The GPR75 Knockout NCI-H1703 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal population of the human non-small cell lung cancer cell line NCI-H1703, carrying a targeted disruption of the GPR75 gene. This knockout model eliminates GPR75 receptor expression, creating a loss-of-function system to interrogate GPR75-dependent signaling and cellular responses.
The NCI-H1703 cell line was established from the pleural effusion of a white male with squamous cell carcinoma of the lung, and serves as a well-characterized model of non-small cell lung cancer (NSCLC). These adherent epithelial cells retain key characteristics of the original tumor, making them suitable for studies of lung cancer biology, drug response, and metastatic mechanisms.
GPR75 is an orphan G protein-coupled receptor that, upon activation, couples to multiple G?? subunits including G??s, G??q, and G??i/o to regulate intracellular second messengers. G??s stimulates adenylyl cyclase to produce cAMP, which activates PKA and downstream transcription factors such as CREB. G??q activates phospholipase C, generating IP3 and DAG, thereby mobilizing calcium and activating PKC. These cascades converge on the MAPK/ERK pathway (Ras-Raf-MEK-ERK) and the PI3K-Akt axis, leading to altered gene expression and cellular phenotypes. Beta-arrestins and G protein-coupled receptor kinases (GRKs) further modulate receptor desensitization and signaling diversity. In the context of NCI-H1703 cells, GPR75 may influence proliferation, survival, and metabolic adaptation.
Knockout of GPR75 in the NCI-H1703 lung cancer background provides a powerful tool to decipher the receptor??s potential contributions to NSCLC pathophysiology. Although GPR75 is primarily studied in metabolic tissues, its expression in lung epithelial cancer cells raises the possibility of uncharacterized oncogenic or tumor-suppressive roles. This polyclonal knockout population enables loss-of-function studies to assess GPR75??s impact on cancer hallmarks such as proliferation, migration, apoptosis, and drug sensitivity, while controlling for the heterogeneity inherent in polyclonal editing.
Researchers can employ these polyclonal GPR75 knockout cells in a variety of downstream functional assays to map GPR75 signaling and its biological consequences. For example, western blotting can detect changes in phosphorylation of ERK1/2 and Akt, while cAMP ELISA and calcium flux assays quantify alterations in second messenger production. Transcriptional responses may be monitored by RT-qPCR for immediate-early genes such as FOS and JUN. Cell-based phenotypic assays including MTT or resazurin viability, wound healing, Transwell migration, and Annexin V/PI apoptosis assays enable comprehensive evaluation of proliferation, motility, and cell death. These applications support drug target validation and mechanistic studies in both lung cancer and metabolic disease research. For more information, please contact Ascent Research.
